Clinical trials: Breast Cancer Recurrent
Breast Cancer
High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003032
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Where
- 25 sites in Canada
- Volunteers
- 224 people
- Sponsor
- NCIC Clinical Trials Group
ER/PR(+), Her2(-) Breast Cancer
Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In Taiwan
Breast cancer is the most common cancer in Taiwanese women. Most of them were diagnosed in relatively early stages. Only 700 metastatic breast cancer were registered in Official Cancer Registration 2012, while more than11,305…
- Trial name
- NCT02924584
- Where
- Taiwan
- Volunteers
- 1 people
- Sponsor
- Pfizer
Breastcancer, Breast Neoplasm
SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
This is a single arm, open label study of SV-BR-1-GM, a targeted immunotherapy for breast cancer. Eligible patients will have histological confirmation of breast cancer with recurrent and/or metastatic lesions.
- Trial name
- NCT03066947
- Testing
- SV-BR-1-GM, Cyclophosphamide, Interferon-alpha-2b
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- BriaCell Therapeutics Corporation
Depression, Stage I Breast Cancer
Factors Affecting Weight Gain in Women Receiving Adjuvant Chemotherapy for Breast Cancer
RATIONALE: Chemotherapy may affect various factors that can lead to weight gain. PURPOSE: Clinical trial to evaluate factors that may affect weight gain in women receiving adjuvant chemotherapy for stage I, stage II, or stage…
- Conditions
- Depression, Stage I Breast Cancer, Stage IIIA Breast Cancer, Nutrition
- Trial name
- NCT00019643
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Locally Advanced Breast Cancer, Metastatic Breast Cancer
A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer
The main purpose of this study is to prove non-inferiority, as well as to demonstrate the comparability of safety and immunogenicity of RPH-051 and Perjeta® in combination with trastuzumab and docetaxel as the 1st line therapy…
- Trial name
- NCT07386938
- Testing
- RPH-051, Docetaxel, Perjeta®
- Where
- 45 sites in Russia
- Volunteers
- 246 people
- Sponsor
- R-Pharm
Anxiety Disorder, Depression
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer
This pilot clinical trial studies stress reduction in improving quality of life in patients with recurrent gynecologic or breast cancer.
- Conditions
- Anxiety Disorder, Depression, Fatigue, Leydig Cell Tumor
- Trial name
- NCT01764789
- Testing
- questionnaire administration, quality-of-life assessment, psychosocial assessment and care
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer
This study is being done to find out how safe TAS-108 is and how well TAS-108 works on recurrent or recurrent inoperable breast cancer.
- Trial name
- NCT00166543
- Testing
- TAS-108
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- SRI International
Breast Cancer
Post-Mastectomy Surveillance to Detect Recurrence in Breast Cancer Patients
Currently, there is no standard recommendation for using imaging studies to check patients for breast cancer recurrence who have been treated with mastectomy.
- Trial name
- NCT02688725
- Testing
- post mastectomy ultrasound
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Providence Health & Services
Metastatic Breast Cancer
Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens
The purpose of this study is to evaluate the efficacy and safety of novel pan-HER inhibitor, NOV120101 (Poziotinib), in HER2-overexpressed recurrent stage IV breast cancer patients who received at least 2 prior HER2-directed…
- Trial name
- NCT02418689
- Testing
- NOV120101 (Poziotinib)
- Where
- 7 sites in South Korea
- Volunteers
- 106 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Breast Cancer
Gene Expression in Predicting Response to Paclitaxel in Patients With Breast Cancer
RATIONALE: DNA analysis of tumor tissue may help doctors predict how patients who receive paclitaxel will respond to treatment. PURPOSE: This laboratory study is evaluating gene expression in predicting response to paclitaxel in…
- Trial name
- NCT00898690
- Testing
- cytogenetic analysis, gene expression analysis, microarray analysis
- Volunteers
- 120 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Breast Cancer, Recurrent Breast Cancer
A Study of Diffusing Alpha Radiation Therapy for Patients With Breast Carcinoma in Frail or Elderly Patients.
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of newly diagnosed or Recurrent Breast Carcinoma in frail or elderly patients.
- Conditions
- Breast Cancer, Recurrent Breast Cancer, Breast Carcinoma
- Trial name
- NCT06202118
- Testing
- Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Alpha Tau Medical LTD.
Estrogen Receptor Positive, HER2/Neu Negative
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer
This phase II trial studies how well Akt inhibitor MK-2206 (MK-2206) and anastrozole with or without goserelin acetate works in treating patients with stage II-III breast cancer.
- Conditions
- Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma, Stage IIA Breast Cancer
- Trial name
- NCT01776008
- Testing
- Akt Inhibitor MK2206, Anastrozole, Goserelin Acetate
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer Metastatic, Breast Cancer Recurrent
Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients
Targeted therapy in the treatment of breast cancer targets HER2 receptor (Human Epidermal growth factor Receptor). HER2 receptor plays an important role in cell growth and differentiation (5).
- Conditions
- Breast Cancer Metastatic, Breast Cancer Recurrent, Breast Cancer Female
- Trial name
- NCT05301010
- Testing
- Faceptor, Herceptin, Docetaxel
- Where
- 2 sites in Vietnam
- Volunteers
- 128 people
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
Breast Cancer
Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane plus goserelin may fight breast cancer by reducing the production of estrogen.
- Trial name
- NCT00010010
- Testing
- exemestane, goserelin acetate
- Where
- United States
- Sponsor
- NYU Langone Health
Breast Cancer
Arsenic Trioxide in Treating Women With Locally Advanced or Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00075413
- Testing
- arsenic trioxide
- Sponsor
- The University of Texas Medical Branch, Galveston
Breast Cancer
Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole +/- goserelin (the latter for pre-menopausal women only) may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT01013506
- Testing
- IGF-1R inhibitor OSI-906, erlotinib hydrochloride, goserelin
- Sponsor
- Vanderbilt-Ingram Cancer Center
Neuropathy, Pain
Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer
This randomized phase III trial studies calcium and magnesium to see how well they work in preventing peripheral neuropathy caused by ixabepilone in patients with breast cancer.
- Conditions
- Neuropathy, Pain, Recurrent Breast Carcinoma, Stage IV Breast Cancer
- Trial name
- NCT00998738
- Testing
- Calcium Gluconate, Magnesium Sulfate, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Breast Cancer, Prostate Cancer
Magnetic Resonance Imaging of Lymph Nodes Using Ferumoxytol in Patients With Primary Prostate or Breast Cancer
RATIONALE: Diagnostic procedures such as magnetic resonance imaging (MRI) using ferumoxytol may improve the ability to detect cancer that has spread to the lymph nodes and may help plan effective cancer treatment.
- Trial name
- NCT00087347
- Testing
- ferumoxytol, magnetic resonance imaging
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer, Kidney Cancer
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Breast Cancer, Kidney Cancer, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00006126
- Testing
- busulfan, cyclophosphamide, etoposide
- Sponsor
- Northwestern University
Breast Cancer
S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using drugs such as anastrozole and fulvestrant may fight breast cancer by blocking the use of estrogen.
- Trial name
- NCT00075764
- Testing
- anastrozole, fulvestrant
- Where
- 426 sites in United States, Canada
- Volunteers
- 695 people
- Sponsor
- SWOG Cancer Research Network